Significantly, an assortment of two mAbs to HER2, pertuzumab and trastuzumab, in conjunction with chemotherapy, considerably prolonged progression-free survival of breast cancer patients whose tumors overexpress HER2 (8)
Significantly, an assortment of two mAbs to HER2, pertuzumab and trastuzumab, in conjunction with chemotherapy, considerably prolonged progression-free survival of breast cancer patients whose tumors overexpress HER2 (8). capability of…